Leniolisib for Immune Dysregulation in CVID

Clinical trial NCT06897358 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06897358
Sponsor: Pharming Technologies B.V.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Common Variable Immunodeficiency (CVID)

Start date: 2025-02-12
Primary completion: 2026-10-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.